Fresenius Medical Care AG & Co. KGaA

NYSE:FMS

Medical - Care Facilities

Healthcare
$20.95 -0.76%

-$0.18 today

Market cap
$11.26B
Beta
0.81
P/E (TTM)
11.9
EPS (TTM)
$3.43
Dividend yield
3.65%
52W Low $20.02High $28.87

Volume 1.92M

Average 0.72M

FMS Purchases of Investments

Cash used to buy marketable securities and other investments.

Fresenius Medical Care AG & Co. KGaANYSE: FMS

Purchases of Investments · Q2 FY2026 · quarter ended Jun 2026

Purchases of investments turns negative

Q2 FY2026 purchases of investments was -€74.41M, compared with €167K a year earlier. Trailing-twelve-month purchases of investments was -€150.44M. Over 3 fiscal years it compounded at -6.6% a year.

Context

  • Purchases of investments amounted to 0.4% of revenue in FY2025, unchanged from a year earlier.
  • Purchases of investments grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly purchases of investments holds near -€74.41M or moves back toward the trailing-twelve-month quarterly average of -€37.61M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-€74.41M+106197.1% QoQ
Last fiscal yearDec 2025
-€85.99M+5.5% YoY
LTMJun 2026
-€150.44M+1219.3% YoY
Purchases of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-44655.7%——
1 year+5.5%——
3-year CAGR-6.6%——
5-year CAGR——
10-year CAGR——

Purchases of Investments history

EUR · from the cash flow

Latest · FY2025
(85.99M) EUR
Year-over-year change
-5.5%

Purchases of Investments vs competitors

How FMS compares with its peers on the latest reported figures

  • Peers report in different currencies, so purchases of investments is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +1219.3% is the highest of 3, against a peer median of +62.2%.
  • Purchases of investments amounts to 0.8% of revenue for FMS, versus a peer median of 0.4%.
FMS Competitors
Purchases of Investments for FMS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TVTXTravere Therapeutics, Inc.LTM Sep 2026$451.24M USD+131.4%-14.9%69.3%
FMSFresenius Medical Care AG & Co. KGaALTM Jun 2026€150.44M EUR+1219.3%-6.6%0.8%
DVADaVita Inc.LTM Jun 2026$49.6M USD-7.1%-44.8%0.4%
AKBAAkebia Therapeutics, Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding FMS) —+62.2%-29.9%0.4%

Competitors are the stored peer set for FMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income1.22B894.33M732.46M740.87M939.75M
Depreciation & Amortization1.62B1.84B1.75B1.74B1.5B
Deferred Income Tax67.26M(41.47M)(122.15M)(72.67M)(26.14M)
Stock-Based Compensation0032.52M00
Change in Working Capital(97.77M)(128.07M)561.28M444.31M132.78M
Accounts Receivables(163.2M)(46.68M)(151.84M)(73.48M)(66.34M)
Inventory(48.53M)(204.31M)(13.14M)107.9M(238.84M)
Accounts Payables(363.96M)(356.79M)108.48M155.59M(14.18M)
Other Working Capital477.91M479.71M617.78M254.3M452.14M
Other Non-Cash Items(322.7M)(395.77M)(327.27M)(468.62M)28.38M
Operating Cash Flow2.49B2.17B2.63B2.39B2.58B
Capital Expenditures(854.36M)(723.99M)(684.6M)(699.36M)(879.24M)
Acquisitions (Net)(381.73M)1.03M137M606.68M223.34M
Purchases of Investments(129.08M)(105.64M)(102.36M)(81.5M)(85.99M)
Sales of Investments144.52M57.67M89.6M75.13M80.2M
Other Investing Activities24.42M36.21M16.14M14.1M0
Investing Cash Flow(1.2B)(734.73M)(544.23M)(84.94M)(666.18M)
Debt Repayment(358.9M)(1.12B)(1.19B)(1.91B)767.1M
Common Stock Issued00000
Common Stock Repurchased0000(562.19M)
Dividends Paid(392.46M)(395.56M)(328.62M)(349.16M)(405.84M)
Other Financing Activities(273.02M)(103.8M)(340.11M)(314.99M)(1.17B)
Financing Cash Flow(1.02B)(1.62B)(1.86B)(2.57B)(1.38B)
Effect of Forex Changes131.23M(23.16M)(72.61M)26.2M24.97M
Net Change in Cash400.12M(207.87M)153.44M(241.9M)558.32M
Free Cash Flow1.64B1.44B1.94B1.69B1.7B

Fresenius Medical Care AG & Co. KGaA

NYSE:FMS

Intrinsic Alpha fair value

Locked

Current Price

$20.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.